RT Journal Article
SR Electronic
T1 MTH-1 inhibition retards mesothelioma progression
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA299
DO 10.1183/1393003.congress-2017.OA299
VO 50
IS suppl 61
A1 Sophia Magkouta
A1 Apostolos Pappas
A1 Chrysavgi Kosti
A1 Marianthi Iliopoulou
A1 Katherina Psarra
A1 Ioannis Kalomenidis
YR 2017
UL http://erj.ersjournals.com/content/50/suppl_61/OA299.abstract
AB MTH1 enzyme sanitizes oxidized dNTP pools to prevent incorporation of damaged bases during DNA replication. MTH1 targeting promotes tumor cell apoptosis without affecting normal cells . Moreover, it reduces ROS levels implying an additional anti-inflammatory and anti-angiogenic role. Since MPM initiation and progression are associated with oxidative stress and genotoxic damage, we assumed that MTH-1 presents a reasonable target for MPM treatment. We hypothesized that pharmacological targeting of the protein would abrogate experimental MPM growth in vivo by inducing tumor cell apoptosis, limiting tumor angiogenesis, and reprogramming pro-tumor immune responses. Our hypothesis was tested in a syngeneic AE17 murine model as well as in ZL34 xenographs. The MTH-1 inhibitor (TH1579) abrogated mesothelioma progression in both models. Mesothelioma-associated pleural effusion was also profoundly reduced in treated mice. Tumors of TH1579-treated mice presented enhanced tumor cell apoptosis and reduced angiogenesis compared to control. In addition to this, TH1579 conferred an M1 anti-tumor phenotype of pleural fluid macrophages. In conclusion, MTH-1 inhibition substantially abrogates mesothelioma progression affecting tumor growth, angiogenesis and tumor-associated inflammation.